Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun 15;83(2):146–152. doi: 10.1054/bjoc.2000.1192

Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma

H E R Ford 1,2, D Cunningham 1, P J Ross 1, S Rao 1, G W Aherne 2, T S Benepal 1, T Price 1, A Massey 1, L Vernillet 3
PMCID: PMC2363476  PMID: 10901362

Abstract

To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of irinotecan and raltitrexed given as sequential short infusions every 3 weeks, 33 patients with pretreated gastrointestinal adenocarcinoma (31 colorectal, 2 oesophagogastric) entered this open label dose-escalation study. For the first five dose levels patients received irinotecan 175–350 mg m–2followed by raltitrexed 2.6 mg m–2. Level VI was irinotecan 350 mg m–2plus raltitrexed 3.0 mg m–2, level VII was irinotecan 400 mg m–2plus raltitrexed 2.6 mg m–2; 261 courses were administered. Only one patient at dose levels I–V experienced DLT. At level VI, 5/12 patients experienced DLT: one had grade 3 diarrhoea and lethargy, one had grade 4 diarrhoea and one had lethargy alone. Two others had lethargy caused by disease progression. There was no first-cycle neutropenia. At level VII, 3/6 patients experienced dose-limiting lethargy, one also had grade 3 diarrhoea. Dose intensity fell from over 90% for both drugs at level VI to 83% for irinotecan and 66% for raltitrexed at level VII. Lethargy was therefore the DLT, and level VII the MTD. Pharmacokinetic data showed no measurable drug interaction; 6/30 patients (20%) had objective responses. This combination is active with manageable toxicity. Recommended doses for further evaluation are irinotecan 350 mg m–2and raltitrexed 3.0 mg m–2. © 2000 Cancer Research Campaign

Keywords: irinotecan, raltitrexed, drug combination, phase I, pharmacokinetics

Full Text

The Full Text of this article is available as a PDF (69.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abigerges D., Armand J. P., Chabot G. G., Da Costa L., Fadel E., Cote C., Hérait P., Gandia D. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst. 1994 Mar 16;86(6):446–449. doi: 10.1093/jnci/86.6.446. [DOI] [PubMed] [Google Scholar]
  2. Abigerges D., Chabot G. G., Armand J. P., Hérait P., Gouyette A., Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 1995 Jan;13(1):210–221. doi: 10.1200/JCO.1995.13.1.210. [DOI] [PubMed] [Google Scholar]
  3. Aherne G. W., Ward E., Lawrence N., Dobinson D., Clarke S. J., Musgrove H., Sutcliffe F., Stephens T., Jackman A. L. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models. Br J Cancer. 1998;77(2):221–226. doi: 10.1038/bjc.1998.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Armand J. P. CPT-11: clinical experience in phase I studies. Semin Oncol. 1996 Feb;23(1 Suppl 3):27–33. [PubMed] [Google Scholar]
  5. Aschele C., Baldo C., Sobrero A. F., Debernardis D., Bornmann W. G., Bertino J. R. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res. 1998 May;4(5):1323–1330. [PubMed] [Google Scholar]
  6. Beale P., Judson I., Hanwell J., Berry C., Aherne W., Hickish T., Martin P., Walker M. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol. 1998;42(1):71–76. doi: 10.1007/s002800050787. [DOI] [PubMed] [Google Scholar]
  7. Chabot G. G., Abigerges D., Catimel G., Culine S., de Forni M., Extra J. M., Mahjoubi M., Hérait P., Armand J. P., Bugat R. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol. 1995 Feb;6(2):141–151. doi: 10.1093/oxfordjournals.annonc.a059109. [DOI] [PubMed] [Google Scholar]
  8. Clarke S. J., Hanwell J., de Boer M., Planting A., Verweij J., Walker M., Smith R., Jackman A. L., Hughes L. R., Harrap K. R. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol. 1996 May;14(5):1495–1503. doi: 10.1200/JCO.1996.14.5.1495. [DOI] [PubMed] [Google Scholar]
  9. Cunningham D., Zalcberg J. R., Rath U., Oliver I., van Cutsem E., Svensson C., Seitz J. F., Harper P., Kerr D., Perez-Manga G. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Ann Oncol. 1996 Nov;7(9):961–965. doi: 10.1093/oxfordjournals.annonc.a010800. [DOI] [PubMed] [Google Scholar]
  10. Giovanella B. C., Stehlin J. S., Wall M. E., Wani M. C., Nicholas A. W., Liu L. F., Silber R., Potmesil M. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science. 1989 Nov 24;246(4933):1046–1048. doi: 10.1126/science.2555920. [DOI] [PubMed] [Google Scholar]
  11. Grem J. L., Sorensen J. M., Cullen E., Takimoto C. H., Steinberg S. M., Chen A. P., Hamilton J. M., Arbuck S. G., McAtee N., Lawrence D. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. Clin Cancer Res. 1999 Sep;5(9):2381–2391. [PubMed] [Google Scholar]
  12. Jackman A. L., Taylor G. A., Gibson W., Kimbell R., Brown M., Calvert A. H., Judson I. R., Hughes L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 1991 Oct 15;51(20):5579–5586. [PubMed] [Google Scholar]
  13. Judson I., Maughan T., Beale P., Primrose J., Hoskin P., Hanwell J., Berry C., Walker M., Sutcliffe F. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694). Br J Cancer. 1998 Nov;78(9):1188–1193. doi: 10.1038/bjc.1998.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Murad A. M., Santiago F. F., Petroianu A., Rocha P. R., Rodrigues M. A., Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993 Jul 1;72(1):37–41. doi: 10.1002/1097-0142(19930701)72:1<37::aid-cncr2820720109>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  15. O'Leary J. J., Shapiro R. L., Ren C. J., Chuang N., Cohen H. W., Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res. 1999 Jan;5(1):181–187. [PubMed] [Google Scholar]
  16. Ross P., Norman A., Cunningham D., Webb A., Iveson T., Padhani A., Prendiville J., Watson M., Massey A., Popescu R. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol. 1997 Oct;8(10):995–1001. doi: 10.1023/a:1008263516099. [DOI] [PubMed] [Google Scholar]
  17. Rougier P., Bugat R., Douillard J. Y., Culine S., Suc E., Brunet P., Becouarn Y., Ychou M., Marty M., Extra J. M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997 Jan;15(1):251–260. doi: 10.1200/JCO.1997.15.1.251. [DOI] [PubMed] [Google Scholar]
  18. Saltz L. B., Kanowitz J., Kemeny N. E., Schaaf L., Spriggs D., Staton B. A., Berkery R., Steger C., Eng M., Dietz A. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol. 1996 Nov;14(11):2959–2967. doi: 10.1200/JCO.1996.14.11.2959. [DOI] [PubMed] [Google Scholar]
  19. Shimada Y., Rothenberg M., Hilsenbeck S. G., Burris H. A., 3rd, Degen D., Von Hoff D. D. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs. 1994 Apr;5(2):202–206. doi: 10.1097/00001813-199404000-00011. [DOI] [PubMed] [Google Scholar]
  20. Webb A., Cunningham D., Scarffe J. H., Harper P., Norman A., Joffe J. K., Hughes M., Mansi J., Findlay M., Hill A. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261–267. doi: 10.1200/JCO.1997.15.1.261. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES